India’s Precision Medicine: A Vision Hindered by Biobank Regulations
Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.
The Promise of Precision Medicine
In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.
India’s Growing Market
The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.
The Biobank Conundrum
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.
A Path Forward
To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.
Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Florida families are feeling the squeeze as everyday costs, insurance premiums, and homeownership barriers continue to climb. House District 102 candidate Jayden D’Onofrio is calling for a broader, more unified affordability strategy—one that tackles the state’s insurance crisis, supports first‑time homebuyers, and restores real competition in the market. His message centers on transparency, practical solutions, and keeping Florida livable for the professionals, workers, and families who power its economy.
A decade of dramatic change is reshaping America’s health insurance markets. Employer group plans are becoming increasingly dominated by a few powerful insurers, while the ACA individual marketplace is experiencing record‑breaking competition and enrollment. Self‑funded plans are surging, small‑group premiums are driving employers to new coverage models, and major policy shifts in 2025 could redefine affordability for millions. This data‑driven Peterson‑KFF analysis breaks down the trends every insurance, finance, and business professional needs to understand as the industry enters a transformative new era.
Sarasota County is inching closer to approving Winchester Ranch, a massive 8,999‑home community planned for more than 3,100 acres in North Port. With a 7‑1 vote from the Planning Commission and a final decision expected in early 2026, the project could become one of Southwest Florida’s largest developments in decades—bringing new housing, commercial space, and industry while raising fresh questions about growth, the environment, and the region’s rapidly evolving real estate market.
Lument Finance Trust has closed a major $663.8 million commercial real estate CLO, marking one of the standout CRE finance deals of 2025. The transaction, LMNT 2025-FL3, features a strong reinvestment period, non‑recourse and non‑mark‑to‑market financing, and a diversified pool of 32 loans tied to 49 properties nationwide. With J.P. Morgan leading the structuring and more than $585 million placed in investment‑grade securities, the deal highlights renewed stability in transitional CRE debt—making it a development real estate and finance professionals will want to watch closely.
Walmart has partnered with Alquist 3D to roll out the nation’s first large‑scale wave of 3D‑printed commercial buildings, signaling a major shift in how future retail and industrial spaces will be constructed. After completing an 8,000‑square‑foot 3D‑printed expansion in Tennessee—the largest of its kind—the company is moving forward with over a dozen new projects nationwide, accelerating a tech‑driven transformation in commercial real estate.
Citizens Property Insurance Corp. is recommending statewide rate reductions for 2026—the first proposed decrease in more than a decade. Most Citizens policyholders could see an average 11.5% drop, reflecting recent insurance‑market reforms that have stabilized Florida’s turbulent property sector. With hundreds of thousands of policies moving back to private insurers and state‑backed Citizens shrinking to record‑low enrollment, real estate and insurance professionals should prepare for how lower premiums may influence affordability, buyer confidence, and market activity heading into 2026.
Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent 
While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the 
